Genomma Lab Internacional B de C : Announces Dividend Payment

Relación con Inversionistas

T. [phone]

[e-mail]

GENOMMA LAB INTERNACIONAL ANNOUNCES DIVIDEND PAYMENT

Mexico City, December 09, 2021 - Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, informs that on November 26, 2021, the Company presented the Notice of Rights, through the Mexican Stock Exchange, communicating the payment of a dividend to shareholders for the total amount of $ 400,000,000.00 M.N. (four hundred million pesos 00/100 National Currency) to be held on December 10, at a rate of $ 0.381679389 mexican pesos for each of the shares representing the capital stock of LABB that are in circulation according to the shareholding and in proportion to their participation in the capital stock of the Company.

The dividend was approved by the Company's Ordinary and Extraordinary Annual General Shareholders Meeting, held on April 27, 2017, delegating to the Board of Directors the faculty to determine the payment dates of said dividend, once the investment phase in the Manufacturing Plant had concluded and once the stage of cash flow generation started alongside important improvements in the quality of our products, as a result of the new infrastructure.

2021 represented the Company's third consecutive year of sustained growth, the result of the renewed vision and strategy implemented since January 2019.

The Company has reported that the first lines of the manufacturing plant are already in operation and that additional lines will begin to operate in the coming months, it also has sufficient resources to invest in the recently announced strategic projects, which in no case would be higher than estimated cost of various product launches that Genomma makes regularly.

Considering the foregoing, the Board of Directors, in the exercise of the faculties delegated by said Assembly, made the decision to make this first payment and evaluate the ideal moment to make another dividend payment of at least the same amount in 2022.

Genomma Lab appreciates the trust placed by its shareholders and financing providers, including the IFC (part of the World Bank) and the Inter-American Development Bank, in order to consolidate the beginning of a new stage of value generation for its shareholders.

Finally, it is noted that the amount that will be paid as dividends to the Company's shareholders comes from the Net Tax Profit Account (CUFIN) prior to 2014.

About Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low‐cost, highly flexible supply chain operating model. For more information visit: www.genommalab.com

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LABB" (Bloomberg: LABB:MM).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products attained by competitors; challenges inherent in new product development; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws; changes in behavior and spending patterns of purchasers of products and services; financial instability of international economies and legal systems and sovereign risk. A further list and descriptions of these risks, uncertainties and other factors can be found within the Company's related filings with the Bolsa Mexicana de Valores. Any forward-looking statement made in this release speaks only as of the date of this release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

https://inversionistas.genommalab.com

1